Neurology 2001;57:658-662
© 2001 American Academy of Neurology
Articles
Clinical markers of early disease in persons near onset of Huntington’s disease
J. S. Paulsen, PhD;,
H. Zhao, ScD;,
J. C. Stout, PhD;,
R. R. Brinkman, BSc;,
M. Guttman, MD;,
C. A. Ross, PhD, MD;,
P. Como, PhD;,
C. Manning, PhD;,
M. R. Hayden, PhD, MD;,
I. Shoulson, MD and
the Huntington Study Group*
From the University of Iowa (Dr. Paulsen), Iowa City; University of Rochester (Drs. Como, Shoulsen, and Zhao), NY; Indiana University (Dr. Stout), Bloomington; University of British Columbia (Dr. Hayden and R. Brinkman), Vancouver, BC, Canada; University of Toronto (Dr. Guttman), Ontario, Canada; Johns Hopkins University (Dr. Ross), Baltimore, MD; and the University of Virginia (Dr. Manning), Charlottesville.
Address correspondence and reprint requests to Dr. Jane S. Paulsen, The University of Iowa, 1-289 MEB, Iowa City, IA 52242-1000; e-mail: jane-paulsen{at}uiowa.edu
Objective:— There is increasing evidence that neuron loss precedes the phenotypic expression of Huntington’s disease (HD). As genes for late-onset neurodegenerative diseases are identified, the need for accurate assessment of phenoconversion (i.e., the transition from health to the disease phenotype) will be important.
Methods:— Prospective longitudinal evaluation using the Unified Huntington’s Disease Rating Scale (UHDRS) was conducted by Huntington Study Group members from 36 sites. There were 260 persons considered "at risk" for HD who initially did not have manifest disease and had at least one subsequent evaluation. Repeat UHDRS data, obtained an average of 2 years later, showed that 70 persons were given a diagnosis of definite HD based on the quantified neurologic examination.
Results:— Baseline cognitive performances were consistently worse for the at-risk group who demonstrated conversion to a definitive diagnosis compared with those who did not. Longitudinal change scores showed that the at-risk group who did not demonstrate manifest disease during the follow-up study period demonstrated improvements in all cognitive tests, whereas performances in the at-risk group demonstrating conversion to disease during the study declined across cognitive domains.
Conclusions:— Neuropsychological measures show impairment 2 years before the development of more manifest motor disease. Findings suggest that these brief cognitive measures administered over time may capture early striatal neural loss in HD.
This article has been cited by other articles:
|
|
|
|
 
J. S. Paulsen and K. Duff
Extending MCI beyond Alzheimer disease
Neurology,
March 31, 2009;
72(13):
1116 - 1117.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Brandt, A. B. Inscore, J. Ward, B. Shpritz, A. Rosenblatt, R. L. Margolis, and C. A. Ross
Neuropsychological Deficits in Huntington's Disease Gene Carriers and Correlates of Early "Conversion"
J Neuropsychiatry Clin Neurosci,
November 1, 2008;
20(4):
466 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J S Paulsen, D R Langbehn, J C Stout, E Aylward, C A Ross, M Nance, M Guttman, S Johnson, M MacDonald, L J Beglinger, et al.
Detection of Huntington's disease decades before diagnosis: the Predict-HD study
J. Neurol. Neurosurg. Psychiatry,
August 1, 2008;
79(8):
874 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Wolf, N. Vasic, C. Schonfeldt-Lecuona, G. B. Landwehrmeyer, and D. Ecker
Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI
Brain,
November 1, 2007;
130(11):
2845 - 2857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. N. Pallier, E. S. Maywood, Z. Zheng, J. E. Chesham, A. N. Inyushkin, R. Dyball, M. H. Hastings, and A. Jennifer Morton
Pharmacological Imposition of Sleep Slows Cognitive Decline and Reverses Dysregulation of Circadian Gene Expression in a Transgenic Mouse Model of Huntington's Disease
J. Neurosci.,
July 18, 2007;
27(29):
7869 - 7878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini
Microglial activation in presymptomatic Huntington's disease gene carriers
Brain,
July 1, 2007;
130(7):
1759 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Langbehn, J. S. Paulsen, and The Huntington Study Group
Predictors of diagnosis in Huntington disease
Neurology,
May 15, 2007;
68(20):
1710 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Blekher, S. A. Johnson, J. Marshall, K. White, S. Hui, M. Weaver, J. Gray, R. Yee, J. C. Stout, X. Beristain, et al.
Saccades in presymptomatic and early stages of Huntington disease
Neurology,
August 8, 2006;
67(3):
394 - 399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Finke, P. Bublak, M. Dose, H. J. Muller, and W. X. Schneider
Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington's disease
Brain,
May 1, 2006;
129(5):
1137 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ciarmiello, M. Cannella, S. Lastoria, M. Simonelli, L. Frati, D. C. Rubinsztein, and F. Squitieri
Brain White-Matter Volume Loss and Glucose Hypometabolism Precede the Clinical Symptoms of Huntington's Disease
J. Nucl. Med.,
February 1, 2006;
47(2):
215 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.C.H. van Oostrom, R. P. Maguire, C. C. Verschuuren-Bemelmans, L. Veenma-van der Duin, J. Pruim, R. A.C. Roos, and K. L. Leenders
Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease
Neurology,
September 27, 2005;
65(6):
941 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kassubek, F. D. Juengling, D. Ecker, and G. B. Landwehrmeyer
Thalamic Atrophy in Huntington's Disease Co-varies with Cognitive Performance: A Morphometric MRI Analysis
Cereb Cortex,
June 1, 2005;
15(6):
846 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Van Raamsdonk, J. Pearson, E. J. Slow, S. M. Hossain, B. R. Leavitt, and M. R. Hayden
Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease
J. Neurosci.,
April 20, 2005;
25(16):
4169 - 4180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Saft, J E Andrich, N Brune, M Gencik, P H Kraus, H Przuntek, and J T Epplen
Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease
J. Neurol. Neurosurg. Psychiatry,
December 1, 2004;
75(12):
1692 - 1696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Paulsen, J. L. Zimbelman, S. C. Hinton, D. R. Langbehn, C. L. Leveroni, M. L. Benjamin, N. C. Reynolds, and S. M. Rao
fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington's Disease
AJNR Am. J. Neuroradiol.,
November 1, 2004;
25(10):
1715 - 1721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Christie and S. M. Hersch
Demonstration of nondeclarative sequence learning in mice: Development of an animal analog of the human serial reaction time task
Learn. Mem.,
November 1, 2004;
11(6):
720 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tost, C. S. Wendt, A. Schmitt, A. Heinz, and D. F. Braus
Huntington's Disease: Phenomenological Diversity of a Neuropsychiatric Condition That Challenges Traditional Concepts in Neurology and Psychiatry
Am J Psychiatry,
January 1, 2004;
161(1):
28 - 34.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. DeKosky and K. Marek
Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders
Science,
October 31, 2003;
302(5646):
830 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Squitieri, C. Gellera, M. Cannella, C. Mariotti, G. Cislaghi, D. C. Rubinsztein, E. W. Almqvist, D. Turner, A.-C. Bachoud-Levi, S. A. Simpson, et al.
Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course
Brain,
April 1, 2003;
126(4):
946 - 955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
